Attached files
| file | filename |
|---|---|
| EX-99.2 - EUROPCR CONFERENCE PRESENTATION - REVA Medical, Inc. | d354388dex992.htm |
| EX-99.1 - INTERIM CLINICAL RESULTS ANNOUNCEMENT - REVA Medical, Inc. | d354388dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: May 17, 2012
(Date of earliest event reported)
REVA MEDICAL, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-54192 | 33-0810505 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 5751 Copley Drive, San Diego, CA | 92111 | |
| (Address of principal executive offices) | (Zip Code) |
(858) 966-3000
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
On May 17, 2012, Dr. Alexandre Abizaid, the Principal Investigator to the RESTORE clinical trial, will present certain information concerning REVA Medical, Inc. (the “Company”) in a slide presentation to attendees at the European Course on Revascularization meeting in Paris, France. The Company is providing a related announcement regarding the presentation. Copies of the slide presentation and the announcement, as filed with the Australian Securities Exchange, are being furnished pursuant to Regulation FD as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. A copy of the slide presentation is also posted under the Investor Relations section of the Company’s website at www.revamedical.com.
In accordance with General Instruction B.2. of Form 8-K, this information, including Exhibits 99.1 and 99.2, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits. |
| Exhibit |
Description | |
| 99.1 | Interim Clinical Results Announcement | |
| 99.2 | EuroPCR Conference Presentation | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| REVA Medical, Inc. | ||||
| Date: May 17, 2012 | /s/ Katrina L. Thompson |
|||
| Katrina L. Thompson | ||||
| Chief Financial Officer | ||||
| (principal financial and accounting officer) | ||||
Index to Exhibits
| Exhibit Number |
Description of Exhibits | |
| 99.1 | Interim Clinical Results Announcement | |
| 99.2 | EuroPCR Conference Presentation | |